Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- LDP’s Takemi Says NHI Prices Will Probably Be Cut for 3 Years in a Row
January 16, 2015
- MHLW Approves Plan to Include Hepatitis B Vaccines in Public Vaccination Programs
January 16, 2015
- 1.9 Billion Yen Allocated to Speed Up Regulatory Reviews
January 15, 2015
- 124.8 Billion Yen Earmarked in FY2015 Budget for AMED
January 15, 2015
- AJMC to Announce Guidelines for Investigator-Led Clinical Trials Next Month
January 15, 2015
- Japan Govt OKs FY2015 Tax Reform Plan
January 15, 2015
- Editor’s Pick: Five Healthcare News Headlines for Dec. 29 - Jan. 11
January 14, 2015
- Cabinet OKs Extra Budget, 3.5 Billion Yen Allocated for IFN-Free Treatment
January 13, 2015
- Panel Agrees to Add Hepatitis B Vaccines to Public Immunization Program
January 13, 2015
- MHLW Calls for Revision of Package Inserts for SGLT-2 Inhibitors
January 13, 2015
- FY2015 Budget to Earmark 47 Billion Yen to Promote Healthcare R&D
January 9, 2015
- PAFSC 2nd Committee to Discuss Eisai’s Anticancer Agent on Jan. 21
January 9, 2015
- 30% R&D Tax Deduction Cap Could Be Secured with Open Innovation Tax Break: Economic Affairs Division
January 8, 2015
- 2015 to Be “Starting Year for Major Reform” of Healthcare and Nursing Insurance Systems: Health Minister
January 8, 2015
- Public Trust Indispensable for Industry Development: Mr Futagawa of Health Policy Bureau
January 7, 2015
- Pharmaceutical and Food Safety Bureau to Promote Prescription-to-OTC Switches Based on Industry Opinions
January 6, 2015
- MHLW OKs 31 Products Including Takeda’s Vonoprazan
January 5, 2015
- Ruling Parties Settle on 25%-Plus-5% Cap for R&D Tax Credit
January 5, 2015
- Health Minister Shiozaki Reappointed
December 25, 2014
- LDP Study Group Shows Sense of Crisis over Reduction of R&D Tax Deduction Cap
December 25, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…